AbbVie Announces Advances in Rheumatic Disease R&D at APLAR 27 AbbVie showcases significant advancements in rheumatic disease research and development at the 27th APLAR conference, highlighting innovative treatments.

AbbVie Announces Advances in Rheumatic Disease R&D at APLAR 27 #Japan #Fukuoka #AbbVie #APLAR #rheumatic_diseases

The role of anifrolumab in reshaping the treatment landscape of extra-renal systemic lupus erythematosus - PubMed Despite its recent approval and limited real-world evidence, anifrolumab has emerged as a promising therapeutic option for non-renal lupus. We hope this review will encourage further studies on the ef...

pubmed.ncbi.nlm.nih.gov/40704391 | #medsky #openaccess #rheumatic_diseases #lupus